Literature DB >> 15612083

Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.

Willie Underwood1, James Jackson, John T Wei, Rodney Dunn, Edmond Baker, Sonya Demonner, David P Wood.   

Abstract

BACKGROUND: African-American men have a greater incidence of and mortality from prostate carcinoma compared with white men, and they are less likely to receive definitive therapy (radical prostatectomy or external beam radiation therapy). During the 1990s, the use of brachytherapy increased; however, its influence on racial and ethnic prostate carcinoma treatment trends remains unclear. The objective of this study was to describe treatment trends over the period 1992-1999 for localized/regional prostate carcinoma among white, Hispanic, and African-American men.
METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) registry data from 1992 through 1999, logistic regression models were used to determine whether the odds of receiving a specific treatment modality differed by racial and ethnic group and whether the differences changed over time when the models were adjusted for age, marital status, tumor grade, and SEER site (geography).
RESULTS: The authors identified 142,340 men, including white men (81.6%), Hispanic men (6.4%), and African-American men (12.0%). Racial and ethnic differences in the rates of use of androgen-deprivation therapy/expectant management were noted; however, these differences appeared to lessen over time (P < 0.001). The rate of utilization of radical prostatectomy increased for Hispanic men, remained flat for African-American men, and decreased for white men. The utilization of brachytherapy and combination therapy increased for all three groups; however, the greatest increase in utilization was among white men.
CONCLUSIONS: Further research will be required to determine the patient-level and provider-level variables that influence racial and ethnic treatment differences in localized/regional prostate cancer. (c) 2004 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15612083     DOI: 10.1002/cncr.20796

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

Review 1.  Evidence-based comparison of robotic and open radical prostatectomy.

Authors:  William T Lowrance; Tatum V Tarin; Shahrokh F Shariat
Journal:  ScientificWorldJournal       Date:  2010-11-16

2.  Men's perspectives on selecting their prostate cancer treatment.

Authors:  Jinping Xu; Rhonda K Dailey; Susan Eggly; Anne Victoria Neale; Kendra L Schwartz
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

3.  African-American Men with Low-Risk Prostate Cancer: Modern Treatment and Outcome Trends.

Authors:  Augustine C Obirieze; Ambria Moten; Delenya Allen; Chiledum A Ahaghotu
Journal:  J Racial Ethn Health Disparities       Date:  2014-12-16

4.  Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?

Authors:  Cary P Gross; Benjamin D Smith; Elizabeth Wolf; Martin Andersen
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

5.  Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.

Authors:  April P Carson; Daniel L Howard; William R Carpenter; Yhenneko J Taylor; Sharon Peacock; Anna P Schenck; Paul A Godley
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

6.  Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urology       Date:  2016-09-22       Impact factor: 2.649

7.  Variation in quality of care among older men with localized prostate cancer.

Authors:  Ravishankar Jayadevappa; Sumedha Chhatre; Jerry C Johnson; S Bruce Malkowicz
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

8.  The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy.

Authors:  Kyna M Gooden; Daniel L Howard; William R Carpenter; April P Carson; Yhenneko J Taylor; Sharon Peacock; Paul A Godley
Journal:  Med Care       Date:  2008-11       Impact factor: 2.983

Review 9.  Insulin: a novel agent in the pathogenesis of prostate cancer.

Authors:  Hanumanthappa Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-07-30       Impact factor: 2.370

10.  Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.

Authors:  Kendra Schwartz; Isaac J Powell; Willie Underwood; Julie George; Cecilia Yee; Mousumi Banerjee
Journal:  Urology       Date:  2009-12       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.